While CTLA-4 inhibitors have shown promise, they also come with challenges. The enhanced immune activity can lead to immune-related adverse events (irAEs), such as colitis, hepatitis, and dermatitis. Managing these side effects requires a delicate balance to ensure that the immune system remains active against the tumor while minimizing harm to healthy tissues.
